nach oben

Pediatric Nephrology

Erschienen in:

16.03.2016 | Educational Review

Diuretics in the treatment of hypertension

verfasst von: Douglas L. Blowey

Erschienen in: Pediatric Nephrology | Ausgabe 12/2016

Einloggen, um Zugang zu erhalten

Abstract

Diuretics have long been used for the treatment of hypertension. Thiazide diuretics are the most commonly prescribed diuretics for hypertension, but other classes of diuretics may be useful in alternative circumstances. Although diuretics are no longer considered the preferred agent for treatment of hypertension in adults and children, they remain acceptable first-line options. Diuretics effectively decrease blood pressure in hypertensive patients, and in adults with hypertension reduce the risk of adverse cardiovascular outcomes. Because of varied pharmacokinetic and pharmacodynamic differences, chlorthalidone may be the preferred thiazide diuretic in the treatment of primary hypertension. Other types of diuretics (e.g., loop, potassium sparing) may be useful for the treatment of hypertension related to chronic kidney disease (CKD) and other varied conditions. Common side effects of thiazides are mostly dose-related and involve electrolyte and metabolic abnormalities.

Nur mit Berechtigung zugänglich

James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC Jr, Svetkey LP, Taler SJ, Townsend RR, Wright JT Jr, Narva AS, Ortiz E (2014) 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 311:507–520CrossRefPubMed

Flack JM, Sica DA, Bakris G, Brown AL, Ferdinand KC, Grimm RH Jr, Hall WD, Jones WE, Kountz DS, Lea JP, Nasser S, Nesbitt SD, Saunders E, Scisney-Matlock M, Jamerson KA, International Society on Hypertension in Blacks (2010) Management of high blood pressure in blacks: an update of the international society on hypertension in blacks consensus statement. Hypertension 56:780–800CrossRefPubMed

Houle SK, Padwal R, Poirier L, Tsuyuki RT (2014) The 2014 Canadian hypertension education program (CHEP) guidelines for pharmacists: an update. Can Pharm J 147:203–208CrossRef

Whitworth JA, World Health Organization, International Society of Hypertension Writing Group (2003) 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 21:1983–1992CrossRefPubMed

Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F, Task Force for the Management of Arterial Hypertension of the European Society of Hypertension and the European Society of Cardiology (2014) 2013 ESH/ESC practice guidelines for the management of arterial hypertension. Blood Press 23:3–16CrossRefPubMed

National Clinical Guideline Centre (2011) Hypertension: the clinical management of primary hypertension in adults: update of clinical guidelines 18 and 34. National Institute for Health and Clinical Excellence: Guidance, London

ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (2002) Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 288:2981–2997CrossRef

Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ, Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute, National High Blood Pressure Education Program Coordinating Committee (2003) Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42:1206–1252CrossRefPubMed

Jones B, Nanra RS (1979) Double-blind trial of antihypertensive effect of chlorothiazide in severe renal failure. Lancet 2:1258–1260CrossRefPubMed

10.

Dussol B, Moussi-Frances J, Morange S, Somma-Delpero C, Mundler O, Berland Y (2012) A pilot study comparing furosemide and hydrochlorothiazide in patients with hypertension and stage 4 or 5 chronic kidney disease. J Clin Hypertens 14:32–37CrossRef

11.

Karadsheh F, Weir MR (2012) Thiazide and thiazide-like diuretics: an opportunity to reduce blood pressure in patients with advanced kidney disease. Curr Hypertens Rep 14:416–420CrossRefPubMed

12.

Agarwal R, Sinha AD (2012) Thiazide diuretics in advanced chronic kidney disease. J Am Soc Hypertens 6:299–308CrossRefPubMed

13.

Taber DJ, Srinivas TM, Pilch NA, Meadows HB, Fleming JN, McGillicuddy JW, Bratton CF, Thomas B, Chavin KD, Baliga PK, Egede LE (2013) Are thiazide diuretics safe and effective antihypertensive therapy in kidney transplant recipients? Am J Nephrol 38:285–291CrossRefPubMed

14.

Gradman AH, Basile JN, Carter BL, Bakris GL, American Society of Hypertension Writing Group (2011) Combination therapy in hypertension. J Clin Hypertens 13:146–154CrossRef

15.

National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents (2004) The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 114(2 Suppl 4th Report):555–576CrossRef

16.

Lurbe E, Cifkova R, Cruickshank JK, Dillon MJ, Ferreira I, Invitti C, Kuznetsova T, Laurent S, Mancia G, Morales-Olivas F, Rascher W, Redon J, Schaefer F, Seeman T, Stergiou G, Wuhl E, Zanchetti A, European Society of Hypertension (2009) Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension. J Hypertens 27:1719–1742CrossRefPubMed

17.

Musini VM, Nazer M, Bassett K, Wright JM (2014) Blood pressure-lowering efficacy of monotherapy with thiazide diuretics for primary hypertension. Cochrane Database Syst Rev 5, CD003824

18.

Carlsen JE, Kober L, Torp-Pedersen C, Johansen P (1990) Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects. BMJ 300:975–978CrossRefPubMedPubMedCentral

19.

Peterzan MA, Hardy R, Chaturvedi N, Hughes AD (2012) Meta-analysis of dose–response relationships for hydrochlorothiazide, chlorthalidone, and bendroflumethiazide on blood pressure, serum potassium, and urate. Hypertension 59:1104–1109CrossRefPubMedPubMedCentral

20.

Reyes AJ (2002) Diuretics in the therapy of hypertension. J Hum Hypertens 16(Suppl 1):S78–S83CrossRefPubMed

21.

Sorof JM, Cargo P, Graepel J, Humphrey D, King E, Rolf C, Cunningham RJ (2002) Beta-blocker/thiazide combination for treatment of hypertensive children: a randomized double-blind, placebo-controlled trial. Pediatr Nephrol 17:345–350CrossRefPubMed

22.

Bachmann H (1984) Propranolol versus chlorthalidone--a prospective therapeutic trial in children with chronic hypertension. Helv Paediatr Acta 39:55–61

23.

Berenson GS, Shear CL, Chiang YK, Webber LS, Voors AW (1990) Combined low-dose medication and primary intervention over a 30-month period for sustained high blood pressure in childhood. J Med Sci 299:79–86CrossRef

24.

Vasavada N, Agarwal R (2003) Role of excess volume in the pathophysiology of hypertension in chronic kidney disease. Kidney Int 64:1772–1779CrossRefPubMed

25.

Vasavada N, Saha C, Agarwal R (2003) A double-blind randomized crossover trial of two loop diuretics in chronic kidney disease. Kidney Int 64:632–640CrossRefPubMed

26.

Zaffanello M, Cataldi L, Franchini M, Fanos V (2010) Evidence-based treatment limitations prevent any therapeutic recommendation for acute poststreptococcal glomerulonephritis in children. Med Sci Monit 16:RA79–RA84PubMed

27.

Tanphaichitr P (1977) Oral furosemide versus conventional therapy for acute poststreptococcal glomerulonephritis in children. J Med Assoc Thail 60:213–217

28.

Musini VM, Rezapour P, Wright JM, Bassett K, Jauca CD (2012) Blood pressure lowering efficacy of loop diuretics for primary hypertension. Cochrane Database Syst Rev 8, CD003825

29.

Weinberger MH, Roniker B, Krause SL, Weiss RJ (2002) Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 15:709–716CrossRefPubMed

30.

Calhoun DA (2007) Low-dose aldosterone blockade as a new treatment paradigm for controlling resistant hypertension. J Clin Hypertens 9(1 Suppl 1):19–24CrossRef

31.

Chapman N, Dobson J, Wilson S, Dahlof B, Sever PS, Wedel H, Poulter NR, Anglo-Scandinavian Cardiac Outcomes Trial Investigators (2007) Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 49:839–845CrossRefPubMed

32.

Lane DA, Shah S, Beevers DG (2007) Low-dose spironolactone in the management of resistant hypertension: a surveillance study. J Hypertens 25:891–894CrossRefPubMed

33.

Li JS, Flynn JT, Portman R, Davis I, Ogawa M, Shi H, Pressler ML (2010) The efficacy and safety of the novel aldosterone antagonist eplerenone in children with hypertension: a randomized, double-blind, dose–response study. J Pediatr 157:282–287CrossRefPubMed

34.

Tamargo J, Segura J, Ruilope LM (2014) Diuretics in the treatment of hypertension. Part 1: thiazide and thiazide-like diuretics. Expert Opin Pharmacother 15:527–547CrossRefPubMed

35.

Brater DC (2011) Update in diuretic therapy: clinical pharmacology. Semin Nephrol 31:483–494CrossRefPubMed

36.

Tamargo J, Segura J, Ruilope LM (2014) Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents. Expert Opin Pharmacother 15:605–621CrossRefPubMed

37.

Ernst ME, Carter BL, Goerdt CJ, Steffensmeier JJ, Phillips BB, Zimmerman MB, Bergus GR (2006) Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 47:352–358CrossRefPubMed

38.

Ernst ME, Neaton JD, Grimm RH Jr, Collins G, Thomas W, Soliman EZ, Prineas RJ, Multiple Risk Factor Intervention Trial Research Group (2011) Long-term effects of chlorthalidone versus hydrochlorothiazide on electrocardiographic left ventricular hypertrophy in the multiple risk factor intervention trial. Hypertension 58:1001–1007CrossRefPubMedPubMedCentral

39.

Roush GC, Buddharaju V, Ernst ME (2013) Is chlorthalidone better than hydrochlorothiazide in reducing cardiovascular events in hypertensives? Curr Opin Cardiol 28:426–432PubMed

40.

Roush GC, Holford TR, Guddati AK (2012) Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses. Hypertension 59:1110–1117CrossRefPubMed

41.

Duarte JD, Cooper-DeHoff RM (2010) Mechanisms for blood pressure lowering and metabolic effects of thiazide and thiazide-like diuretics. Expert Rev Cardiovasc Ther 8:793–802CrossRefPubMedPubMedCentral

42.

Wilson IM, Freis ED (1959) Relationship between plasma and extracellular fluid volume depletion and the antihypertensive effect of chlorothiazide. Circulation 20:1028–1036CrossRefPubMed

43.

Tarazi RC, Dustan HP, Frohlich ED (1970) Long-term thiazide therapy in essential hypertension. Evidence for persistent alteration in plasma volume and renin activity. Circulation 41:709–717CrossRefPubMed

44.

van Brummelen P, Man In't Veld AJ, Schalekamp MA (1980) Hemodynamic changes during long-term thiazide treatment of essential hypertension in responders and nonresponders. Clin Pharmacol Ther 27:328–336CrossRefPubMed

45.

Cruz DN, Simon DB, Nelson-Williams C, Farhi A, Finberg K, Burleson L, Gill JR, Lifton RP (2001) Mutations in the Na-Cl cotransporter reduce blood pressure in humans. Hypertension 37:1458–1464CrossRefPubMed

46.

Hadchouel J, Delaloy C, Faure S, Achard JM, Jeunemaitre X (2006) Familial Hyperkalemic hypertension. J Am Soc Nephrol 17:208–217CrossRefPubMed

47.

Ji W, Foo JN, O'Roak BJ, Zhao H, Larson MG, Simon DB, Newton-Cheh C, State MW, Levy D, Lifton RP (2008) Rare independent mutations in renal salt handling genes contribute to blood pressure variation. Nat Genet 40:592–599CrossRefPubMedPubMedCentral

48.

Turner ST, Schwartz GL, Chapman AB, Boerwinkle E (2005) WNK1 kinase polymorphism and blood pressure response to a thiazide diuretic. Hypertension 46:758–765CrossRefPubMed

49.

Kannel WB, Schwartz MJ, McNamara PM (1969) Blood pressure and risk of coronary heart disease: the Framingham study. Dis Chest 56:43–52CrossRefPubMed

50.

Wright JM, Musini VM (2009) First-line drugs for hypertension. Cochrane Database Syst Rev 3, CD001841

51.

Cheng JW (2013) Azilsartan/chlorthalidone combination therapy for blood pressure control. Integr Blood Press Control 6:39–48CrossRefPubMedPubMedCentral

52.

Multiple Risk Factor Intervention Trial Research Group (1982) Multiple risk factor intervention trial. Risk factor changes and mortality results. JAMA 248:1465–1477CrossRef

53.

Dorsch MP, Gillespie BW, Erickson SR, Bleske BE, Weder AB (2011) Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis. Hypertension 57:689–694CrossRefPubMed

54.

Sarafidis PA, Georgianos PI, Lasaridis AN (2010) Diuretics in clinical practice. Part II: electrolyte and acid–base disorders complicating diuretic therapy. Expert Opin Drug Saf 9:259–273CrossRefPubMed

55.

van Blijderveen JC, Straus SM, Rodenburg EM, Zietse R, Stricker BH, Sturkenboom MC, Verhamme KM (2014) Risk of hyponatremia with diuretics: chlorthalidone versus hydrochlorothiazide. Am J Med 127:763–771CrossRefPubMed

56.

Siscovick DS, Raghunathan TE, Psaty BM, Koepsell TD, Wicklund KG, Lin X, Cobb L, Rautaharju PM, Copass MK, Wagner EH (1994) Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med 330:1852–1857CrossRefPubMed

57.

Sjogren A, Edvinsson L, Fallgren B (1989) Magnesium deficiency in coronary artery disease and cardiac arrhythmias. J Intern Med 226:213–222CrossRefPubMed

58.

Elliott WJ, Meyer PM (2007) Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 369:201–207CrossRefPubMed

59.

Ueda S, Morimoto T, Ando S, Takishita S, Kawano Y, Shimamoto K, Ogihara T, Saruta T, Investigators DIME (2014) A randomised controlled trial for the evaluation of risk for type 2 diabetes in hypertensive patients receiving thiazide diuretics: diuretics in the management of essential hypertension (DIME) study. BMJ Open 4, e004576CrossRefPubMedPubMedCentral

60.

Strom BL, Schinnar R, Apter AJ, Margolis DJ, Lautenbach E, Hennessy S, Bilker WB, Pettitt D (2003) Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. N Engl J Med 349:1628–1635CrossRefPubMed

Titel: Diuretics in the treatment of hypertension
verfasst von: Douglas L. Blowey
Publikationsdatum: 16.03.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: Pediatric Nephrology / Ausgabe 12/2016
Print ISSN: 0931-041X
Elektronische ISSN: 1432-198X
DOI: https://doi.org/10.1007/s00467-016-3334-4

Neu im Fachgebiet Pädiatrie

18.04.2024 | Spinale Muskelatrophien | Nachrichten

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Diuretics in the treatment of hypertension

Abstract

Neu im Fachgebiet Pädiatrie

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

Zunahme von Geschlechtsinkongruenz und -dysphorie registriert

Intrakapsuläre Tonsillektomie gewinnt an Boden

Update Pädiatrie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2016

Renal failure from birth—AKI or CKD? Answers

Acute kidney injury due to rotavirus gastroenteritis-associated obstructive uric acid stones in a Japanese infant harboring a heterozygous W258X mutation

Comparison of cotrimoxazole vs. second-generation cephalosporins for prevention of urinary tract infections in children

Loss of function of NaPiIIa causes nephrocalcinosis and possibly kidney insufficiency

Timing of renal replacement therapy does not influence survival and growth in children with congenital nephrotic syndrome caused by mutations in NPHS1: data from the ESPN/ERA-EDTA Registry

Reviews submitted from September 1st, 2015 to August 31st, 2016

Neu im Fachgebiet Pädiatrie

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

Zunahme von Geschlechtsinkongruenz und -dysphorie registriert

Intrakapsuläre Tonsillektomie gewinnt an Boden

Update Pädiatrie